Evidence map›Paper›PMID 39057932›Full record

ArticleToxins2024

Allo-Hemodialysis, a Novel Dialytic Treatment Option for Patients with Kidney Failure: Outcomes of Mathematical Modelling, Prototyping, and

Vaibhav Maheshwari, Nadja Grobe, Xin Wang, Amrish Patel, Alhaji Cherif, Xia Tao, Joshua Chao, Alexander Heide, Dejan Nikolic, Jiaming Dong and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Vaibhav MaheshwariRenal Research Institute, 315 East 62nd Street, 3rd Floor, New York, NY 10065, USA.
Nadja GrobeRenal Research Institute, 315 East 62nd Street, 3rd Floor, New York, NY 10065, USA.ORCID 0000-0001-9812-7672
Xin WangRenal Research Institute, 315 East 62nd Street, 3rd Floor, New York, NY 10065, USA.
Amrish PatelRenal Research Institute, 315 East 62nd Street, 3rd Floor, New York, NY 10065, USA.
Alhaji CherifRenal Research Institute, 315 East 62nd Street, 3rd Floor, New York, NY 10065, USA.
Xia TaoRenal Research Institute, 315 East 62nd Street, 3rd Floor, New York, NY 10065, USA.
Joshua ChaoRenal Research Institute, 315 East 62nd Street, 3rd Floor, New York, NY 10065, USA.
Alexander HeideFresenius Medical Care, 61352 Bad Homburg, Germany.
Dejan NikolicFresenius Medical Care, 61352 Bad Homburg, Germany.
Jiaming DongFresenius Medical Care, Shanghai 200030, China.
Peter KotankoRenal Research Institute, 315 East 62nd Street, 3rd Floor, New York, NY 10065, USA.ORCID 0000-0003-4373-412X

Funding

Renal Research Institute n/a
6 · The paper itself

Abstract

It has been estimated that in 2010, over two million patients with end-stage kidney disease may have faced premature death due to a lack of access to affordable renal replacement therapy, mostly dialysis. To address this shortfall in dialytic kidney replacement therapy, we propose a novel, cost-effective, and low-complexity hemodialysis method called allo-hemodialysis (alloHD). With alloHD, instead of conventional hemodialysis, the blood of a patient with kidney failure flows through the dialyzer's dialysate compartment counter-currently to the blood of a healthy subject (referred to as a "buddy") flowing through the blood compartment. Along the concentration and hydrostatic pressure gradients, uremic solutes and excess fluid are transferred from the patient to the buddy and subsequently excreted by the healthy kidneys of the buddy. We developed a mathematical model of alloHD to systematically explore dialysis adequacy in terms of weekly standard urea

Indexed as

Renal DialysisAdultAnuriaChildHumansKidney Failure, ChronicMaleModels, TheoreticalRenal InsufficiencyUreaUreaacid–base dynamicsalloHDallo-hemodialysishemodialysisurea kinetic modeling

Identifiers

PMID39057932
PMCPMC11281302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.